{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T16:13:17Z","timestamp":1649002397504},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[1996,8,1]],"date-time":"1996-08-01T00:00:00Z","timestamp":838857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":8559,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1996,8]]},"DOI":"10.1093\/oxfordjournals.annonc.a010677","type":"journal-article","created":{"date-parts":[[2012,4,18]],"date-time":"2012-04-18T21:46:43Z","timestamp":1334785603000},"page":"601-605","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of metastatic renal cell carcinoma with constant-rate floxuridine infusion plus recombinant \u03b12b-interferon"],"prefix":"10.1016","volume":"7","author":[{"given":"A.","family":"Falcone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Pfanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lencioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Brunetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.C.","family":"Giulianotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Vannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.F.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ssu.2980040302","article-title":"Prognostic factors of adult renal carcinoma: Multivariate analyses","volume":"4","author":"De Forges","year":"1988","journal-title":"Semin Surg Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0010","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0022-5347(17)39992-5","article-title":"Radical extensive surgery for renal cell carcinoma; Long term results and prognostic factors","volume":"143","author":"Giuliani","year":"1990","journal-title":"J Urol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0015","first-page":"42","article-title":"Chemotherapy for advanced renal-cell carcinoma: 1983\u20131993","volume":"22","author":"Yagoda","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0020","series-title":"Cancer Principle and Practice of Oncology","first-page":"1023","article-title":"Cancer of the kidney and ureter","author":"WM Linehan","year":"1993"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0025","first-page":"143","article-title":"Therapeutic challenges in the medical management of renal cancer","volume":"2","author":"Boccardo","year":"1991","journal-title":"Forum"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0030","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/0959-8049(94)90179-1","article-title":"Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-\u03b1","volume":"30A","author":"Fossa","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/cbr.1993.8.275","article-title":"The impact of interleukin-2 on survival in renal cancer: A multivariate analysis","volume":"8","author":"Jones","year":"1993","journal-title":"Cancer Biother"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0040","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1200\/JCO.1991.9.5.832","article-title":"Vinblasine fails to improve response of renal cancer to interferon alfa-n1: High response rate in patients with pulmonary metastases","volume":"9","author":"Neidhart","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00000421-198902000-00010","article-title":"Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma","volume":"12","author":"Sertoli","year":"1989","journal-title":"Am J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0050","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1200\/JCO.1990.8.9.1504","article-title":"Circadian-shaped infusions of floxuridine for progressive meta-static renal cell carcinoma","volume":"8","author":"Hrushesky","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0055","first-page":"16","article-title":"Advances in chemotherapy for renal cell carcinoma","volume":"10","author":"Huben","year":"1992","journal-title":"Semin Urol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0060","first-page":"139","article-title":"A phase II study of constant rate FUDR infusion in patients with metastatic renal cell carcinoma","volume":"9","author":"Wilkinson","year":"1990","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/1097-0142(19900715)66:2<237::AID-CNCR2820660207>3.0.CO;2-F","article-title":"Orcadian continous chemotherapy of renal cell carcinoma with an implantable programmable infusion pump","volume":"66","author":"Damascelli","year":"1990","journal-title":"Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0070","first-page":"233","article-title":"Flat versus circadian modified 14 day infusion of FUDR for advanced renal cell cancer: A phase III study","volume":"13","author":"Bjarnason","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0075","first-page":"4868","article-title":"Interferon effect upon the adenocarci-noma 38 and HL-60 cell lines: Antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites","volume":"48","author":"Elias","year":"1988","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0080","first-page":"5834","article-title":"Translational regulation of thymidylate synthase in response to 5-fluorouracil and gamma-interferon in a human colon cancer cell line","volume":"50","author":"Chu","year":"1990","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0085","first-page":"4243","article-title":"Locus of the interaction among 5-fluorouracil, leucovorin, and interferon \u03b1-2a in colon carcinoma cells","volume":"53","author":"Houghton","year":"1993","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0090","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.1991.9.10.1806","article-title":"Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma","volume":"9","author":"Wadler","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0095","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1200\/JCO.1991.9.10.1811","article-title":"A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma","volume":"9","author":"Grem","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0100","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/1097-0142(19930715)72:2<564::AID-CNCR2820720238>3.0.CO;2-P","article-title":"Alpha-2B interferon plus floxuridine in metastatic renal cell carcinoma. A phase I\u2013II study","volume":"72","author":"Falcone","year":"1993","journal-title":"Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0105","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1002\/1097-0142(19900601)65:11<2451::AID-CNCR2820651108>3.0.CO;2-3","article-title":"Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma","volume":"65","author":"Fossa","year":"1990","journal-title":"Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0110","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/0277-5379(87)90295-1","article-title":"Improved subjective tolerability of interferon by combination with prednisolone","volume":"23","author":"Fossa","year":"1987","journal-title":"Eur J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0115","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Controlled Clinical Trials"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0125","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/oxfordjournals.annonc.a058239","article-title":"Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2","volume":"3","author":"Palmer","year":"1992","journal-title":"Ann Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0130","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000148942","article-title":"Inhibition by interferon of thymi-dine uptake in chemostat cultures of L1210 cells","volume":"9","author":"Brouty-Boye","year":"1978","journal-title":"Intervirology"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0135","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1432-1033.1981.tb05362.x","article-title":"Inhibition of cell division by interferons: Changes in the transport and intracellular meta-bolism of thymidine in human lymphoblastoid (Daudi) cells","volume":"116","author":"Gewert","year":"1981","journal-title":"Eur J Biochem"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0140","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1042\/bj2140983","article-title":"Inhibition of cell division by interferons: The relationship between changes in utilization of thymidine for DNA synthesis and control of proliferation in Daudi cells","volume":"214","author":"Gewert","year":"1983","journal-title":"Biochem J"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0145","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.1993.11.4.751","article-title":"Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer","volume":"11","author":"Danhauser","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0150","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/jnci\/84.23.1820","article-title":"Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and inter-feron \u03b1-2a","volume":"84","author":"Yee","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0155","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1200\/JCO.1995.13.6.1297","article-title":"Royal Marsden phase III trial of fluorouracil with or without interferon alfa 2b in advanced colorectal cancer","volume":"13","author":"Hill","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0160","first-page":"194","article-title":"Weekly high dose infusional 5-fluorouracil (FU) plus leucovorin (LV) vs. FU plus \u03b1-interferon (IFN) vs. FU plus LV plus IFN in advanced colorectal cancer. Results of a multicenter randomized trial","volume":"14","author":"Kohne","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0165","first-page":"209","article-title":"A randomized assessment of interferon-\u03b12a as a modulator of 5-fluorouracil and leucovorin in advanced colorectal cancer","volume":"13","author":"Seymour","year":"1994","journal-title":"Proc Am Ass Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0170","first-page":"186","article-title":"Evidence of additive anti-tumor activity and toxicity for the combination of FUDR and interferon alpha2B in patients with metastatic renal cell carcinoma","volume":"32","author":"Dimopulos","year":"1991","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0175","first-page":"236","article-title":"Phase II trial of continuous infusion floxuridine and interferon-alpha-2b in advanced renal cancer - an NBSG study","volume":"12","author":"Soori","year":"1991","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0180","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00685550","article-title":"Continous infusion fluorodeoxyuridine with leucovorin and high-dose interferon: A phase II study in metastatic renal-cell cancer","volume":"31","author":"Stadler","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1093\/oxfordjournals.annonc.a010677_bb0185","first-page":"273A","article-title":"Recombinant interferon-\u03b1 combined with 5-fluorouracil based chemotherapy in metastatic renal cell cancer","volume":"145","author":"Sella","year":"1991","journal-title":"J Urol"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF00877251","article-title":"A Hoosier Oncology group study: A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma","volume":"10","author":"Murphy","year":"1992","journal-title":"Invest New Drugs"},{"issue":"Suppl 6","key":"10.1093\/oxfordjournals.annonc.a010677_bb0195","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0959-8049(93)91933-C","article-title":"Response in patients with metastatic renal cell carcinoma during the treatment with alpha interferon in combination with 5-fluorouracil","volume":"29","author":"Schuth","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a010677_bb0200","first-page":"237","article-title":"Interleukin-2 with interferon-\u03b1 and 5-fluorouracil in patients with metastatic renal cell cancer","volume":"13","author":"Sella","year":"1994","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 5","key":"10.1093\/oxfordjournals.annonc.a010677_bb0205","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/0959-8049(93)90617-O","article-title":"Interleukin-2 in combination with interferon-\u03b1 and 5-fluorouracil for meta-static renal cell cancer","volume":"29A","author":"Atzpodien","year":"1993","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419655341?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419655341?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/7\/6\/601\/481387\/7-6-601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:48:29Z","timestamp":1582253309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419655341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,8]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1996,8]]}},"alternative-id":["S0923753419655341"],"URL":"https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a010677","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1996,8]]}}}